Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific

Wednesday, May 7, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), Bristol-Myers Squibb Co. (BMY) and Canadian Pacific Kansas City Ltd. (CP), as well a micro-cap stock Nova LifeStyle, Inc. (NVFY). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets in the Green: Disney Beats, Fed Report AwaitsToday's Featured Research ReportsShares of Verizon Communications have gained +12.8% over the past six months against the Zacks Wireless National industry’s gain of +13.5%. The company recorded relatively healthy first-quarter 2025 results with both the top and bottom lines beating the Zacks Consensus Estimate. With one of the most efficient wireless networks in the U.S., the company continues to deploy advanced technologies to deliver faster peak data speeds and capacity for customers, driven by customer-focused planning, disciplined engineering and constant strategic investment. Its focus on mix-and-match pricing across wireless and home broadband offerings has contributed to solid customer additions. The continued expansion of 5G mmWave in multiple markets is a positive development. However, fierce competition from major players is hurting VZ’s profits. Heavy promotional spending and discounts to drive subscriber growth are putting pressure on margins. Macroeconomic challenges remain a concern.(You can read the full research report on Verizon Communications here >>>)Bristol-Myers Squibb shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+14.3% vs. -17.6%). The company reported better-than-expected first quarter results driven by higher demand for Opdivo, Breyanzi, Reblozyl and Camzyos. Consequently, the annual guidance was raised to reflect this performance. Recent label expansions of blockbuster oncology drug Opdivo should fuel further growth. However, generic competition for Revlimid, Pomalyst, Sprycel and Abraxane is adversely impacting revenue growth.  While the performance of new drugs such as Opdualag, Camzyos and Cobenfy is encouraging, they will take some time to make a significant contribution to the top line. Nonetheless, Bristol Myers’ efforts to streamline operations should boost the bottom line. Shares of the company are driven by the encouraging efforts to boost both top-line and bottom-line growth.(You can read the full research report on Bristol-Myers Squibb here >>>)Shares of Canadian Pacific have declined -9.4% over the past year against the Zacks Transportation - Rail industry’s decline of -12.6%. The company’s high operating expenses continue to weigh on the company's bottom line. CP's highly leveraged balance sheet is also a cause for worry. High capex may also create headwinds. Considering all these factors, investors are advised not to bet on the stock now. They should wait for a better entry point.Nevertheless, following the approval of the merger with Kansas City Southern, the company is known as Canadian Pacific Kansas City Limited. The deal is anticipated to draw synergies (annually) of $1 billion within three years. The merged entity has started to offer a daily premium intermodal service between the U.S. Midwest and Mexico. The Zacks analyst is impressed with Canadian Pacific Kansas City's efforts to reward its shareholders through dividends and share repurchases.(You can read the full research report on Canadian Pacific here >>>)Nova LifeStyle’s shares have underperformed the Zacks Furniture industry over the past year (-51.6% vs. -28.1%). This microcap company with market capitalization of $14 million is facing ongoing losses, revenue contraction, high administrative costs and execution risk in portfolio revamp challenge scalability and margin stability amid macro demand sensitivity.Nevertheless, Nova LifeStyle’s 2024 gross margin rose to 44% from 38% as the firm exited low-margin products and boosted average selling price (ASP) by 43%, despite a 12.6% sales decline. Operating expenses fell 9.2%, lowering net loss to $5.6 million from $7.7 million, but general and administrative costs rose 19.8%, and research and development (R&D) cuts limited innovation gains. A revamped product mix and North America focus (97.4% of sales) support pricing power, yet a 39% volume drop and Asian market exit signal weak demand. Sourcing diversification to Vietnam, India and Malaysia mitigates trade risk, though reliance on third-party vendors raises delivery and quality concerns.(You can read the full research report on Nova LifeStyle here >>>)Other noteworthy reports we are featuring today include Diageo plc (DEO), TC Energy Corp. (TRP) and Edwards Lifesciences Corp. (EW).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadDiverse Product Portfolio, Strategic Alliances Aid Verizon (VZ)New Drugs Fuel Bristol Myers (BMY) Amid Generic Competition Canadian Pacific (CP) Rides on Dividends Amid Rising ExpensesFeatured ReportsProductivity Initiatives to Aid Diageo (DEO) Amid InflationPer the Zacks analyst, Diageo is refining its $2 billion productivity program to drive efficiency across the business while ensuring long-term sustainable growth and balancing cost savings.TC Energy's (TRP) Vast Pipeline Network Fuels Future Growth The Zacks analyst believes that TC Energy's robust pipeline infrastructure and gas storage assets offer a solid foundation for future growth, but its debt of over C$45 billion remains a concern.Edwards (EW) Rides on Solid TMTT Sales and Global ProspectsEdwards' strong TMTT sales globally is a major positive. Per the Zacks analyst, differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes are the key drivers.Strong Demand, Expansion Actions Aid Nucor (NUE)While Nucor faces headwinds from weak selling prices, it will benefit from strong demand in its major markets and efforts to boost production capacity, per the Zacks analyst.Healthy Demand Aid Equity Residential (EQR) Amid High SupplyPer the Zacks Analyst, healthy demand to sustain the occupancy level and support revenue growth for Equity Residential. However, elevated supply in some markets and high interest expenses ail.Defense Orders Drive Leidos (LDOS), Amid Labor ShortagePer the Zacks analyst, Leidos Holdings is likely to benefit from increasing defense order growth from the Pentagon and US allies. Yet labor shortage result in delays and likely impact operating resultStrategic Buyouts to Aid Genuine Parts (GPC) Amid Tariff WoesAcquisitions of MPEC and Walker has strengthened Genuine Parts' NAPA store network and Midwest footprint. However, cost pressures due to tariffs may limit the firm's profits, per the Zacks analyst.New UpgradesJuniper (JNPR) Rides on Healthy Demand Trends, AI FocusPer the Zacks analyst, solid momentum in the Cloud and Enterprise verticals will likely drive Juniper's top line. A strong focus on advancing the AI networking portfolio is a tailwind.Encompass Health (EHC) Gains From Expansionary MeasuresThe Zacks Analyst believes that Encompass Health's expansion through de novo hospitals will drive patient volumes and profit levels.Paylocity (PCTY) Rides on Strong Demand for Cloud SolutionsPer the Zacks analyst, Paylocity is benefiting from strong adoption of its cloud-based Human Capital Management (HCM) and payroll software solutions tailored for mid-sized businesses. New DowngradesRising Expenses & Oil Price Volatility Ail SM Energy (SM)Per the Zacks analyst, SM Energy's profits suffer due to falling oil prices and rising lease operating and transportation costs, threatening future revenue and cash???flow stability.PC Market Weakness Hurts Dell Technologies (DELL) ProspectsPer the Zacks analyst, Dell is suffering from a challenging macroeconomic environment. It suffers from stiff competition in the PC market from the likes of HP and Lenovo.Soft OSB Segment & Macro Woes Hurt Louisiana-Pacific (LPX)Per the Zacks analyst, Louisiana-Pacific is hurting from to lower selling prices and decreased sales volumes in the OSB segment. Also, rising costs from expected tariffs are added concerns.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Diageo plc (DEO): Free Stock Analysis Report Canadian Pacific Kansas City Limited (CP): Free Stock Analysis Report TC Energy Corporation (TRP): Free Stock Analysis Report Nova Lifestyle, Inc (NVFY): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks